Show simple item record

dc.contributor.advisorAhmed, Syeda Maliha
dc.contributor.authorSiddika, Khadiza
dc.date.accessioned2024-10-03T05:41:43Z
dc.date.available2024-10-03T05:41:43Z
dc.date.copyright©2024
dc.date.issued2024-04
dc.identifier.otherID 19346027
dc.identifier.urihttp://hdl.handle.net/10361/24296
dc.descriptionThis thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.en_US
dc.descriptionCataloged from PDF version of thesis.
dc.descriptionIncludes bibliographical references (pages 24-28).
dc.description.abstractOver the past two decades, the approval of targeted biologics has significantly transformed therapeutic landscapes, particularly for chronic diseases like cancer. These therapies, specifically target diseases' molecular pathways, offer enhanced efficacy and fewer side effects than traditional chemotherapy. This review assesses the trends in regulatory approval by the FDA, noting a surge in approvals for targeted biologics over the last two decades. The shift towards targeted biologics promises more precise management of the complexities of cancer. This review compiles the FDA's trends in approving targeted biologics for cancer from January 2000 to December 2022 based on product class, rate of approvals, biological target, and disease site. Despite the advancements in targeted cancer therapies, there is a need to comprehensively understand the evolving trends in FDA approvals during the twenty-first century. This study investigates the approval patterns, identifies influencing factors, and provides insights that can contribute to optimizing the development and processes of targeted biologics. This may serve as a good insight for researchers in academia and industry to identify fields in which cancer research and funding may be mostly directed.en_US
dc.description.statementofresponsibilityKhadiza Siddika
dc.format.extent33 pages
dc.language.isoenen_US
dc.publisherBrac Universityen_US
dc.rightsBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectMolecular pathwayen_US
dc.subjectTargeted biologicsen_US
dc.subjectCancer therapyen_US
dc.subjectFDAen_US
dc.subject.lcshBiologicals.
dc.titleTrend in approval of targeted biologics in the last two decadesen_US
dc.typeThesisen_US
dc.contributor.departmentSchool of Pharmacy, Brac University
dc.description.degreeB. Pharmacy


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record